Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in ...

Older people who repeatedly took the common painkiller had an increase risk of conditions ranging from heart failure to ...

A concerning new study has revealed links between regular paracetamol usage and several life-threatening health issues ...

Prolonged paracetamol use was linked to a 35% higher risk of lower gastrointestinal bleeding and around a fifth higher risk ...

Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

The presentation highlights XORTX recent pioneering discoveries in the field of Autosomal Dominant Polycystic Kidney Disease (“ADPKD”), and recent peer-reviewed, independent, published research ...

Patients with early breast cancer who are older may experience high-grade immune-related side effects after receiving immune ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...